FGFR inhibitor · small molecule
rogaratinib
0 active trials across 2 of our biomarkers, targeting FGFR1-4. Not approved for any biomarker on marked.bio yet.
Also known as BAY 1163877.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| FGFR2 fusion or rearrangement | 0 | 2 | – |
| FGFR3 alteration (mutation or fusion) | 0 | 2 | – |
Trials
0 of 2 trials shown
-
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
rogaratinibpalbociclibfulvestrant
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementBreast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
-
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
…stratified according to high fibroblast growth factor receptor (FGFR) expression levels / FGFR mutation using archival or fresh tumor biopsy material
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementNeoplasms
No trials match these filters.